Company Overview

Gilead Sciences, Inc. is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing medicines for life-threatening diseases. The company primarily operates in the biotechnology and pharmaceutical industries, with major therapeutic focus areas including HIV/AIDS, viral hepatitis, oncology, and inflammatory diseases. Gilead’s revenue base is heavily driven by its HIV portfolio, which includes long-acting and oral antiretroviral therapies marketed globally. The company also generates significant revenue from oncology products and antiviral therapies for liver diseases and COVID-19.

Gilead’s core business lines include antiviral therapeutics, cell therapies, and oncology medicines. Key commercial products include Biktarvy, Descovy, Genvoya, Veklury (remdesivir), Trodelvy, and Yescarta. The company serves hospitals, specialty clinics, government health systems, and retail and specialty pharmacies across developed and emerging markets. Gilead is recognized for its leadership in HIV treatment and prevention, supported by extensive intellectual property, long-term clinical development programs, and established global distribution capabilities. Founded in 1987 and headquartered in Foster City, California, Gilead evolved from an antiviral-focused biotechnology company into a diversified biopharmaceutical enterprise through internal research and major acquisitions, including Kite Pharma and Immunomedics.

Business Operations

Gilead organizes its operations primarily around therapeutic and commercial product categories rather than standalone public operating subsidiaries. Its largest revenue-generating segment is the HIV business, which includes treatment and prevention products sold globally. Additional business activities include Oncology, Liver Disease, and other antiviral therapies. The company derives revenue mainly from product sales, licensing arrangements, and collaborative agreements. According to disclosures in SEC filings, the United States represents the company’s largest market, although Europe and other international regions contribute materially to total revenue.

The company controls substantial intellectual property portfolios related to antiviral compounds, biologics, and cell therapies. Through subsidiaries including Kite Pharma, Gilead maintains capabilities in CAR-T cell therapy manufacturing and commercialization. Major partnerships include collaborations with biotechnology firms, academic institutions, and global healthcare organizations to expand therapeutic pipelines and geographic reach. Gilead has also maintained strategic manufacturing and commercialization partnerships in international markets, particularly in low- and middle-income countries for HIV and hepatitis treatments through voluntary licensing frameworks.

Strategic Position & Investments

Gilead’s strategic direction has centered on expanding beyond antivirals into oncology and immunology while maintaining leadership in HIV therapeutics. The company has invested heavily in long-acting HIV treatment and prevention technologies, oncology drug development, and cell therapy infrastructure. Major acquisitions include Kite Pharma in 2017, which expanded Gilead into CAR-T oncology treatments, and Immunomedics in 2020, which added the antibody-drug conjugate Trodelvy to its oncology portfolio. The company has also invested in partnerships involving next-generation immunotherapies and inflammatory disease research.

The company continues to allocate capital toward clinical-stage assets, manufacturing expansion, and strategic collaborations. Emerging areas of focus include oncology combinations, biologic therapies, and advanced cellular therapies. Gilead has also pursued investments in antiviral preparedness and infectious disease platforms following the commercialization of Veklury during the COVID-19 pandemic. Public filings and investor materials indicate that management views oncology diversification and sustained HIV innovation as core long-term growth priorities.

Geographic Footprint

Gilead Sciences is headquartered in Foster City, California, and operates across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. The company maintains commercial, manufacturing, and research operations in multiple countries, with substantial market activity in the United States and major European healthcare markets. International operations include direct commercial infrastructure as well as partnerships with regional distributors and healthcare organizations.

The company’s therapies are marketed in more than 35 countries directly, with broader global access facilitated through licensing and distribution agreements. Gilead has established a notable presence in global HIV treatment access initiatives, particularly in developing regions through partnerships supporting generic manufacturing and public health distribution. Manufacturing and research activities are distributed across the United States and selected international sites, supporting both biologics and cell therapy production capabilities.

Leadership & Governance

Gilead’s leadership structure combines pharmaceutical commercialization experience with biotechnology research expertise. The company’s strategic direction has emphasized scientific innovation, disciplined capital allocation, and expansion into oncology and inflammatory diseases while preserving leadership in antiviral medicine. Governance oversight is provided through a board of directors and executive leadership team disclosed in SEC filings and annual reports.

Key executives include:

• Daniel O’Day – Chairman and Chief Executive Officer
• Andrew Dickinson – Chief Financial Officer
• Dietmar Berger – Chief Medical Officer
• Merdad Parsey – Chief Scientific Officer
• Johanna Mercier – Chief Commercial Officer
• Flavius Martin – Executive Vice President, Research
• Jason Hirsch – General Counsel and Corporate Secretary

Gilead was originally founded by Michael L. Riordan in 1987. Under current leadership, the company has emphasized portfolio diversification, global access initiatives, oncology expansion, and continued investment in research-driven therapeutic development.